Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

 FDA approves leading solution for latent tuberculosis diagnostics, advancing global effort to fight infectious diseases

Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This milestone marks a significant advancement in the fight against TB with a faster high-throughput solution delivering accurate diagnostic results to support timely treatment and containment in the U.S. as well as other locations around the world.

https://www.businesswire.com/news/home/20250402936376/en/Revvity-Secures-FDA-Approval-for-Improved-Automated-Latent-Tuberculosis-Test